Hyundai Bioscience is recruiting Bae Byung-joon, former chairman of the National Clinical Trial Support Foundation and an expert in health and medical policy planning, as the president in charge of strategy. Starting in February, the new president will oversee Hyundai Bioscience’s new drug development and commercialization planning and strategy targeting the global market.
To advance the success of global clinical trials and commercialization of Hyundai Bio's general antiviral drug Zefty for respiratory infections, dengue fever, and Empox, CEO Bae plans to focus on rapid clinical progress and obtaining emergency use approval through smooth cooperation with international organizations such as the U.S. National Institutes of Health (NIH) and the Food and Drug Administration (FDA).
President Bae, who completed his master's degree at Harvard University's Kennedy School, is known to have a strong network of connections overseas, including in the United States. He is expected to contribute to leading a cooperative and collaborative system with health authorities such as the Ministry of Health and Welfare, the Ministry of Food and Drug Safety, and the Korea Disease Control and Prevention Agency for the globalization of Zefty and Polytaxel by leveraging his long-term experience in the health sector in Korea.
- See more related articles
You must be logged in to post a comment.